Next Article in Journal
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Next Article in Special Issue
Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir
Previous Article in Journal
Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs
Previous Article in Special Issue
Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis
Open AccessArticle

Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus

College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
Department of Microbiology and Immunology, College of Medicine, The University of Illinois at Chicago, Chicago, IL 60612, USA
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, and UICentre, University of Illinois at Chicago, Chicago, IL 60612, USA
State Key Laboratory of Bioactive Substances and Function of Natural Medicine, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China
Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX 78227, USA
Department of Microbiology, Boston University, National Emerging Infectious Diseases Laboratories, 401P, 620 Albany Street, Boston, MA 02118, USA
Authors to whom correspondence should be addressed.
Viruses 2018, 10(12), 678;
Received: 6 October 2018 / Revised: 28 November 2018 / Accepted: 29 November 2018 / Published: 30 November 2018
(This article belongs to the Collection Advances in Ebolavirus, Marburgvirus, and Cuevavirus Research)
Ebola virus is the causative agent of Ebola virus disease in humans. The lethality of Ebola virus infection is about 50%, supporting the urgent need to develop anti-Ebola drugs. Glycoprotein (GP) is the only surface protein of the Ebola virus, which is functionally critical for the virus to attach and enter the host cells, and is a promising target for anti-Ebola virus drug development. In this study, using the recombinant HIV-1/Ebola pseudovirus platform we previously established, we evaluated a small molecule library containing various quinoline compounds for anti-Ebola virus entry inhibitors. Some of the quinoline compounds specifically inhibited the entry of the Ebola virus. Among them, compound SYL1712 was the most potent Ebola virus entry inhibitor with an IC50 of ~1 μM. The binding of SYL1712 to the vial glycoprotein was computationally modeled and was predicted to interact with specific residues of GP. We used the time of the addition assay to show that compound SYL1712 blocks Ebola GP-mediated entry. Finally, consistent with being an Ebola virus entry inhibitor, compound SYL1712 inhibited infectious Ebola virus replication in tissue culture under biosafety level 4 containment, with an IC50 of 2 μM. In conclusion, we identified several related molecules with a diaryl-quinoline scaffold as potential anti-EBOV entry inhibitors, which can be further optimized for anti-Ebola drug development. View Full-Text
Keywords: EBOV; entry inhibitor; quinoline; glycoprotein; lead compound; assay EBOV; entry inhibitor; quinoline; glycoprotein; lead compound; assay
Show Figures

Figure 1

MDPI and ACS Style

Cui, Q.; Cheng, H.; Xiong, R.; Zhang, G.; Du, R.; Anantpadma, M.; Davey, R.A.; Rong, L. Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus. Viruses 2018, 10, 678.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop